‘Prolor Biotech’: Positive Results In Hemophilia Drug Trial

Prolor Biotech Inc. reported positive results in a study of its new version of the hemophilia drug Factor VIIa-CTP in a pre-clinical trial on mice. The study showed that mice which received the longer-acting version of the drug showed a higher survival and recovery rate over a longer period of time, compared to those that received the commercially available version of the drug. According to the company, mice that received Factor VIIa-CTP also showed a longer-lasting generation of the pro-clotting enzyme ‘thrombin.’ View and share